29th Nov 2021 14:14
Belluscura PLC - London-based oxygen enrichment technology developer - Receives second reimbursement code under the US government's Medicare health insurance scheme for the X-PLO2R portable oxygen concentrator. Medicare Administrative Contractor Palmetto GBA MolDx issues a final local coverage determination for the machine. Medicare reimbursement covers half the oxygen concentrator market in the US, so Belluscura says the two reimbursement codes will "have a positive impact on the company", which it will detail with its full-year results in early January.
Current stock price: 99.10 pence, up 9.5% on Monday
Year-to-date change: doubled from 45p listing price in May
By Tom Waite; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Belluscura